Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy
Deregulation of the tumor necrosis factor (TNF) plays an important role in the initiation and perpetuation of chronic inflammation and has been implicated in the development of various autoimmune diseases. Accordingly, TNF-inhibitors are successfully used for the treatment of several diseases, such...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-03-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2073-4468/4/1/48 |
| _version_ | 1811203231292850176 |
|---|---|
| author | Roman Fischer Roland E. Kontermann Olaf Maier |
| author_facet | Roman Fischer Roland E. Kontermann Olaf Maier |
| author_sort | Roman Fischer |
| collection | DOAJ |
| description | Deregulation of the tumor necrosis factor (TNF) plays an important role in the initiation and perpetuation of chronic inflammation and has been implicated in the development of various autoimmune diseases. Accordingly, TNF-inhibitors are successfully used for the treatment of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. However, total inhibition of TNF can cause severe side effects such as an increased risk of inflammation and reactivation of tuberculosis. This is likely due to the different actions of the two TNF receptors. Whereas TNFR1 predominantly promotes inflammatory signaling pathways, TNFR2 mediates immune modulatory functions and promotes tissue homeostasis and regeneration. Therefore, the specific blockage of TNFR1 signaling, either by direct inhibition with TNFR1-selective antagonists or by targeting soluble TNF, which predominantly activates TNFR1, may prevent the detrimental effects associated with total TNF-inhibitors and constitute a next-generation approach to interfere with TNF. |
| first_indexed | 2024-04-12T02:51:12Z |
| format | Article |
| id | doaj.art-caebf86fe255414da9aba04478dc5a27 |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-04-12T02:51:12Z |
| publishDate | 2015-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-caebf86fe255414da9aba04478dc5a272022-12-22T03:50:59ZengMDPI AGAntibodies2073-44682015-03-0141487010.3390/antib4010048antib4010048Targeting sTNF/TNFR1 Signaling as a New Therapeutic StrategyRoman Fischer0Roland E. Kontermann1Olaf Maier2Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, GermanyInstitute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, GermanyInstitute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, GermanyDeregulation of the tumor necrosis factor (TNF) plays an important role in the initiation and perpetuation of chronic inflammation and has been implicated in the development of various autoimmune diseases. Accordingly, TNF-inhibitors are successfully used for the treatment of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. However, total inhibition of TNF can cause severe side effects such as an increased risk of inflammation and reactivation of tuberculosis. This is likely due to the different actions of the two TNF receptors. Whereas TNFR1 predominantly promotes inflammatory signaling pathways, TNFR2 mediates immune modulatory functions and promotes tissue homeostasis and regeneration. Therefore, the specific blockage of TNFR1 signaling, either by direct inhibition with TNFR1-selective antagonists or by targeting soluble TNF, which predominantly activates TNFR1, may prevent the detrimental effects associated with total TNF-inhibitors and constitute a next-generation approach to interfere with TNF.http://www.mdpi.com/2073-4468/4/1/48antibodiesautoimmune diseasesinflammationneurodegenerationTNFTNF receptors |
| spellingShingle | Roman Fischer Roland E. Kontermann Olaf Maier Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy Antibodies antibodies autoimmune diseases inflammation neurodegeneration TNF TNF receptors |
| title | Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy |
| title_full | Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy |
| title_fullStr | Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy |
| title_full_unstemmed | Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy |
| title_short | Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy |
| title_sort | targeting stnf tnfr1 signaling as a new therapeutic strategy |
| topic | antibodies autoimmune diseases inflammation neurodegeneration TNF TNF receptors |
| url | http://www.mdpi.com/2073-4468/4/1/48 |
| work_keys_str_mv | AT romanfischer targetingstnftnfr1signalingasanewtherapeuticstrategy AT rolandekontermann targetingstnftnfr1signalingasanewtherapeuticstrategy AT olafmaier targetingstnftnfr1signalingasanewtherapeuticstrategy |